EPX-100 (Clemizole Hydrochloride) ( DrugBank: Clemizole )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
140	Dorabe syndrome	2

140. Dorabe syndrome

---

Clinical trials : 104 /  Drugs : 61 - (DrugBank : 14) / Drug target genes : 48 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04462770 (ClinicalTrials.gov)	September 15, 2020	6/7/2020	EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome	A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Patients With Dravet Syndrome	Dravet Syndrome	Drug: EPX-100 (Clemizole HCl);Drug: Placebo	Epygenix	NULL	Recruiting	2 Years	80 Years	All	60	Phase 2	United States;Canada
2	NCT04069689 (ClinicalTrials.gov)	August 29, 2019	22/8/2019	Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.	A Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to Assess Safety and Pharmacokinetics of Escalating Single and Multiple Oral Doses of EPX-100 in Fasting Healthy Subjects and Following a High-Fat Meal	Dravet Syndrome	Drug: EPX-100 (Clemizole Hydrochloride);Drug: Placebos	Epygenix	NULL	Completed	18 Years	50 Years	All	24	Phase 1	United States